Phosphatidylcholine

Summary

Phosphatidylcholine (CHEMBL503481) is a phase-3 clinical-stage small molecule; indicated across 4 conditions including injury and autoimmune hepatitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 14
• Chemistry: 798.2 Da · C40H80NO8PS2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL503481
Name	Phosphatidylcholine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	25223701
Molecular formula	C40H80NO8PS2
Molecular weight	798.2
InChIKey	ZZWQHNRGJQENEP-KXQOOQHDSA-N

SMILES: CCCCCCCCCCCCCCSCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CSCCCCCCCCCCCCCC

IUPAC name: [(2R)-2,3-bis[(2-tetradecylsulfanylacetyl)oxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate

Also known as: Phosphatidylcholine, Phospholipids egg, phosphatidylcholine, PHOSPHATIDYLCHOLINE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
injury	3	MONDO:0021178	EFO:0000546
autoimmune hepatitis	3	MONDO:0016264	EFO:0005676
ulcerative colitis	2	MONDO:0005101	EFO:0000729

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
Not specified	8
PHASE3	2
PHASE1	2
PHASE1/PHASE2	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02517385	PHASE3	COMPLETED	Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases
NCT06256445	PHASE3	COMPLETED	Evaluate the Efficacy and Safety of AYP-101 for the Reduction of Submental Fat in Chin Area
NCT01905605	PHASE1/PHASE2	WITHDRAWN	Phosphatidylcholine Supplementation in Infants
NCT05266729	PHASE2	COMPLETED	Determine the Dosing Interval and Optimal Dose of AYP-101 for the Reduction of Submental Fat in Chin Area
NCT02633696	PHASE1	COMPLETED	Study to Investigate the Absolute Bioavailability of Oral Sylibin
NCT05476094	PHASE1	COMPLETED	Evaluate Pharmacokinetic/Pharmacodynamic and Safety/Tolerability of AYP-101 in Healthy Subjects
NCT06922669	Not specified	RECRUITING	Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia
NCT07476885	Not specified	NOT_YET_RECRUITING	A Real World Study of Polyene Phosphatidylcholine Injection for the Prevention and Treatment of DILI in Patients With Malignant Hematological Diseases
NCT00006061	Not specified	COMPLETED	Study of Phosphatidylcholine in a Patient With Methionine Adenosyltransferase Deficiency
NCT00678925	Not specified	COMPLETED	Supplemental Choline and Brain Development in Humans
NCT00757081	Not specified	COMPLETED	Study to Evaluate the Effect of Injection Lypolysis (Lipodissolve) Treatments to Reduce Body Fat
NCT00851747	Not specified	TERMINATED	A Study of the Efficacy of Subcutaneous Phosphatidylcholine and Deoxycholate Injections for Localized Fat Removal
NCT02403804	Not specified	COMPLETED	Dietary Supplementation to Increase Serum Choline Levels
NCT03039023	Not specified	COMPLETED	Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).